HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study
PLoS Medicine — Bergqvist R, Ahlqvist VH, Lundberg M, et al. | October 19, 2021
Lipid-lowering HMG-CoA reductase inhibitors (statins) are reported to have pleiotropic effects on coagulation and immune mechanisms. Considering this, researchers herein examined the correlation of statin treatment with COVID-19 mortality.
Swedish health registers yielded data of a cohort of 963,876 residents of Stockholm, Sweden.
Follow-up of the cohort was done from March 1, 2020 until November 11, 2020.
Researchers matched prescription dispensation data to healthcare data and the Swedish Cause of Death Registry.
Multivariable cause-specific survival analysis was conducted to analyze the data.
After accounting for a series of preexisting health conditions and other factors, there appeared a moderately lower risk of COVID-19 mortality in correlation with receiving statin treatment.
Sensitivity analyses corroborated the association and no substantial variation in this association was recorded across risk groups.
Read the full article on PLoS Medicine